Anti amphiphysin
Reading File
Reading File
Finding Sources
Searching PubMed
amphiphysin AND paraneoplastic
Searching the Web
anti-amphiphysin antibody paraneoplastic syndrome clinical significance
Anti-amphiphysin antibody is a neural autoantibody associated with paraneoplastic neurologic syndromes, meaning an immune reaction related to an underlying cancer can affect the nervous system.
Most characteristic associations:
- Stiff-person spectrum disorder: painful muscle stiffness, spasms, exaggerated startle, impaired walking
- Paraneoplastic myelopathy/myelitis
- Sensory neuronopathy or peripheral neuropathy
- Less commonly cerebellar or brainstem syndromes
It is particularly associated with breast cancer and small-cell lung cancer (SCLC). In stiff-person syndrome, an amphiphysin-positive result is more suggestive of a cancer-associated form than the more common anti-GAD65 form. Harrison's notes that amphiphysin antibodies usually indicate a paraneoplastic cause related to SCLC or breast cancer.
A positive result should be interpreted alongside the clinical syndrome and preferably confirmed with appropriate serum/CSF testing by a neurologist. It generally warrants a careful search for an occult malignancy, often including breast evaluation and chest imaging, even if initial screening is unrevealing. The neurological syndrome may be treated with symptomatic drugs and immunotherapy, but identifying and treating the tumor is central. A Neurology review/case discussion describes the broader association with sensory neuronopathy and CNS involvement, while this report illustrates amphiphysin-associated paraneoplastic myelitis and stiff-person syndrome.
This antibody result is not by itself a cancer diagnosis, but it is clinically significant and merits prompt specialist evaluation.
Stiff-person spectrum disorder
Reading File
Finding Sources
Finding Sources
Searching PubMed
"stiff-person syndrome"
Searching the Web
stiff person spectrum disorder diagnosis management consensus 2025
Reading File
Reading File
Reading File
Reading Article
PMID: 41273190
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12053319
Stiff-person spectrum disorder (SPSD)
SPSD is a rare autoimmune neurologic disorder in which reduced inhibitory signaling in the spinal cord and brainstem, mainly GABA and glycine signaling, leads to involuntary, persistent muscle activity.
Core symptoms
- Gradually progressive muscle stiffness and rigidity, typically beginning in the lower back, abdomen, and legs
- Painful muscle spasms, often severe
- Spasms triggered by sound, touch, sudden movement, emotional stress, cold, or startle
- Difficulty walking, falls, hyperlordosis, or a stiff/robotic gait
- Symptoms often lessen during sleep
EMG may show continuous motor-unit activity in affected muscles. Bradley and Daroff's Neurology in Clinical Practice, p. 1752.
Spectrum phenotypes
| Phenotype | Main pattern |
|---|---|
| Classic stiff-person syndrome | Axial and proximal leg stiffness with stimulus-sensitive painful spasms |
| Stiff-limb syndrome | Stiffness and dystonic posture predominantly confined to one or more limbs |
| SPS-plus | SPS with cerebellar, brainstem, seizure, or encephalitic features |
| PERM - progressive encephalomyelitis with rigidity and myoclonus | More severe form with rigidity, jerks/myoclonus, brainstem signs, autonomic instability, and sometimes impaired consciousness |
Bradley and Daroff's Neurology in Clinical Practice, p. 1752.
Antibodies and associated conditions
- Anti-GAD65: most common in classic SPS, often associated with other autoimmune disease such as type 1 diabetes or thyroid autoimmunity.
- Anti-glycine receptor (GlyR): more associated with PERM and can have a better immunotherapy response.
- Anti-amphiphysin: strongly raises concern for paraneoplastic SPSD, especially with breast cancer or small-cell lung cancer.
- Some people are antibody-negative, so a negative panel does not exclude SPSD.
For someone with your prior question about anti-amphiphysin, SPSD is a particularly relevant clinical syndrome. Amphiphysin-positive SPSD should prompt neurologic evaluation and an appropriate search for an underlying malignancy. Harrison's Principles of Internal Medicine, p. 863.
How it is diagnosed
Diagnosis is clinical, supported by:
- Characteristic rigidity and stimulus-triggered spasms
- EMG showing continuous motor-unit activity
- Serum and sometimes CSF neural antibody testing
- MRI and other tests to rule out spinal cord disease, dystonia, tetanus, functional neurologic disorder, medication effects, and other mimics
- Cancer screening when anti-amphiphysin or other paraneoplastic features are present
Recent data support using both objective EMG findings and appropriately interpreted antibodies rather than diagnosing SPSD from a low-positive antibody result alone. Diagnostic study
Treatment
Treatment is individualized and usually combines:
- Symptom control: benzodiazepines such as diazepam, baclofen, gabapentin or related agents, pain management, and carefully paced physiotherapy.
- Immunotherapy: IVIG is a commonly used first-line immune treatment; corticosteroids, plasma exchange, rituximab, or other immunotherapy may be considered in selected or refractory cases.
- Tumor-directed treatment: essential when SPSD is paraneoplastic, especially anti-amphiphysin positive.
Evidence remains limited because SPSD is uncommon and trials are small, so management is best led by a neurologist with neuroimmunology/paraneoplastic expertise. A 2025 systematic review found substantial variation and limited high-quality evidence across immune and symptomatic treatments.
Seek urgent care now for
- Trouble breathing, choking, or difficulty swallowing
- Sustained whole-body spasms, repeated falls, or inability to walk safely
- New confusion, severe jerking, fainting, unstable blood pressure/heart rate, or fever
These may indicate severe SPSD/PERM or another urgent neurologic illness.
This is a shared conversation. Sign in to Orris to start your own chat.